Mantle Cell Lymphoma Mcl clinical trials

Explore recruiting mantle cell lymphoma mcl clinical trials.

Recruiting mantle cell lymphoma mcl studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mantle Cell Lymphoma Mcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Italy, France, Sweden, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO)

Denmark, Sweden, Norway, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma

Denmark, Norway, Sweden, Finland

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)

Portugal, Belgium, Czechia, Austria, Denmark, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA)

Finland, Norway, Denmark, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Mantle Cell Lymphoma Mcl trials by city

Mantle Cell Lymphoma Mcl clinical trials

Recruiting mantle cell lymphoma mcl studies right now

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

CD70-targeted immunoPET Imaging of Malignant Cancers

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

A Long-term Extension Study of PCI-32765 (Ibrutinib)

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

Also recruiting in Europe

A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO)

ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)

Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)

Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA)

Mantle Cell Lymphoma Mcl trials by city

Other conditions